Collectively, these results demonstrated that CCL5-deficienty promotes the migration of CD8+ T cells into tumor and increases the antitumor immune response of CD8+ T cells to inhibit tumor growth and metastasis. The gene discussed is CD8A; the disease is neoplasm.